Hyloris Pharmaceuticals SA ( (DE:52U) ) just unveiled an announcement.
Hyloris Pharmaceuticals reported a significant increase in revenue and a reduction in net losses for 2024, driven by growth in royalties and milestones. The company achieved key milestones, including the launch of Maxigesic® IV in the U.S. and multiple out-licensing deals. With a robust pipeline and strategic partnerships, Hyloris is positioned for continued growth and innovation in addressing unmet medical needs.
More about Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA is a specialty biopharma company focused on addressing unmet medical needs by reinventing existing medications. The company is engaged in product development and commercialization, with a portfolio that includes 24 product candidates, three of which are commercialized. Hyloris is expanding its pipeline and has strategic partnerships to enhance patient access to differentiated medicines.
YTD Price Performance: -14.29%
Average Trading Volume: 292
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €179.2M
For detailed information about 52U stock, go to TipRanks’ Stock Analysis page.